Cargando…

Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells

BACKGROUND: Multiple toll-like receptors (TLRs) are expressed in cells of the monocytic lineage, including microglia, which constitute the major reservoir for human immunodeficiency virus (HIV) infection in the brain. We hypothesized that TLR receptor mediated responses to inflammatory conditions by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarez-Carbonell, David, Garcia-Mesa, Yoelvis, Milne, Stephanie, Das, Biswajit, Dobrowolski, Curtis, Rojas, Roxana, Karn, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294768/ https://www.ncbi.nlm.nih.gov/pubmed/28166799 http://dx.doi.org/10.1186/s12977-017-0335-8

Ejemplares similares

The Glucocorticoid Receptor Is a Critical Regulator of HIV Latency in Human Microglial Cells
por: Alvarez-Carbonell, David, et al.
Publicado: (2018)

Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency
por: Nguyen, Kien, et al.
Publicado: (2017)

Cross-talk between microglia and neurons regulates HIV latency
por: Alvarez-Carbonell, David, et al.
Publicado: (2019)

HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency
por: Llewellyn, George N., et al.
Publicado: (2017)

Recruitment of the CoREST transcription repressor complexes by Nerve Growth factor IB-like receptor (Nurr1/NR4A2) mediates silencing of HIV in microglial cells
por: Ye, Fengchun, et al.
Publicado: (2022)

Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system
por: Garcia-Mesa, Yoelvis, et al.
Publicado: (2016)

Entry of Polarized Effector Cells into Quiescence Forces HIV Latency
por: Dobrowolski, Curtis, et al.
Publicado: (2019)

Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir
por: Das, Biswajit, et al.
Publicado: (2018)

A new BET on the control of HIV latency
por: Karn, Jonathan
Publicado: (2013)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Control of HIV Latency by Epigenetic and Non-Epigenetic Mechanisms
por: Mbonye, Uri, et al.
Publicado: (2011)

Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis
por: Li, Qing, et al.
Publicado: (2016)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
por: Kwon, Somin, et al.
Publicado: (2019)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

Biogenesis of P-TEFb in CD4(+) T cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling pathways
por: Mbonye, Uri, et al.
Publicado: (2021)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Tracking HIV Rebound following Latency Reversal Using Barcoded HIV
por: Marsden, Matthew D., et al.
Publicado: (2020)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells
por: Redlich, Sandra, et al.
Publicado: (2013)

Diverse effects of interferon alpha on the establishment and reversal of HIV latency
por: Van der Sluis, Renée M., et al.
Publicado: (2020)

HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
por: Denton, Paul W.
Publicado: (2022)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies
por: Khanal, Sushant, et al.
Publicado: (2021)

Inhibition of the H3K27 demethylase UTX enhances the epigenetic silencing of HIV proviruses and induces HIV-1 DNA hypermethylation but fails to permanently block HIV reactivation
por: Nguyen, Kien, et al.
Publicado: (2021)

Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2
por: Kim, Changyoun, et al.
Publicado: (2016)

Glycolysis downregulation is a hallmark of HIV‐1 latency and sensitizes infected cells to oxidative stress
por: Shytaj, Iart Luca, et al.
Publicado: (2021)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

A Comparison of Different Immune Activation Strategies to Reverse HIV-1 Latency
por: Garliss, Caroline C, et al.
Publicado: (2020)

Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
por: Meås, Hany Zekaria, et al.
Publicado: (2020)

Latency reversal plus natural killer cells diminish HIV reservoir in vivo
por: Kim, Jocelyn T., et al.
Publicado: (2022)

A truncated HIV Tat demonstrates potent and specific latency reversal activity
por: Van Gulck, Ellen, et al.
Publicado: (2023)

Bioinformatics and HIV Latency
por: Ciuffi, Angela, et al.
Publicado: (2015)

Hypothermia Reduces Toll-Like Receptor 3-Activated Microglial Interferon-β and Nitric Oxide Production
por: Matsui, Tomohiro, et al.
Publicado: (2013)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy
por: Prins, Henrieke A. B., et al.
Publicado: (2023)

HIV latency reversal research and the potential effects on the central nervous system: is concern warranted?
por: Anderson, Albert M, et al.
Publicado: (2016)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sc2fvieujnnol607jatu03trft